Literature DB >> 3501375

Prospective randomized comparison of two prophylactic regimens with trimethoprim-sulfamethoxazole in leukemic children: a two year study.

M R Rossi1, P Banfi, M Cappuccilli, V Conter, D de Poli, G Piacentini, M G Zurlo, G Masera.   

Abstract

Between 1 July 1984 and 30 June 1986 all children treated for acute hematologic malignancy at our center were randomized to receive continuous (group A) or intermittent (3 days/week, group B) prophylaxis with trimethoprim-sulfamethoxazole (5-25 mg/kg/day/p.o.) against interstitial pneumonia with the aim of investigating if an intermittent regimen is as effective as and less toxic than a continuous regimen. The number of severe infections (group A, 17; group B, 21) and side-effects (group A, 30; group B, 34) was similar in the two groups, and compliance was also similar. We conclude therefore that neither regimen offers advantages over the other and the decision which to use should be based on cost (where regimen B has the advantage) and the children's and parents' preferences and compliance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501375     DOI: 10.1016/0277-5379(87)90449-4

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  4 in total

Review 1.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.

Authors:  Anat Stern; Hefziba Green; Mical Paul; Liat Vidal; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-10-01

2.  Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis.

Authors:  Mahmoud Abouraya; James C Sacco; Brad S Kahl; Lauren A Trepanier
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

3.  An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital.

Authors:  L J Worth; M J Dooley; J F Seymour; L Mileshkin; M A Slavin; K A Thursky
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

4.  Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation.

Authors:  Thomas Lehrnbecher; Brian T Fisher; Bob Phillips; Sarah Alexander; Roland A Ammann; Melissa Beauchemin; Fabianne Carlesse; Elio Castagnola; Bonnie L Davis; L Lee Dupuis; Grace Egan; Andreas H Groll; Gabrielle M Haeusler; Maria Santolaya; William J Steinbach; Marianne van de Wetering; Joshua Wolf; Sandra Cabral; Paula D Robinson; Lillian Sung
Journal:  Clin Infect Dis       Date:  2020-06-24       Impact factor: 9.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.